Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLQ | O75417 | 3/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | CACNA1G | O43497 | 8/20 | 0.33 |
| ▸ | CACNA1H | O95180 | 8/20 | 0.33 |
| ▸ | CACNA1I | Q9P0X4 | 7/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.32 |
| ▸ | EEF2K | O00418 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19321081 | 0.92 | POLQ (0.35) | POLQOPRM1CACNA1GCACNA1HCACNA1I | |
| SCHEMBL19326164 | 0.88 | POLQ (0.32) | POLQ | |
| SCHEMBL19140209 | 0.85 | OPRM1 (0.35) | POLQOPRM1CACNA1GCACNA1HCACNA1I | |
| SCHEMBL19325970 | 0.85 | MGLL (0.38) | POLQACHE | |
| SCHEMBL19325959 | 0.85 | CACNA1G (0.38) | OPRM1CACNA1GCACNA1HCACNA1IGABRA1 | |
| SCHEMBL19326035 | 0.85 | GABRA1 (0.36) | OPRM1CACNA1GCACNA1HCACNA1IGABRA1 | |
| SCHEMBL19321076 | 0.84 | CACNA1G (0.37) | OPRM1CACNA1GCACNA1HCACNA1IGABRA1 | |
| SCHEMBL19320896 | 0.84 | CACNA1G (0.42) | OPRM1CACNA1GCACNA1HCACNA1IGABRA1 | |
| SCHEMBL19140996 | 0.82 | OPRM1 (0.33) | POLQOPRM1CACNA1GCACNA1HCACNA1I | |
| SCHEMBL19321184 | 0.80 | POLQ (0.32) | POLQACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170253607-A1 | LONG-ACTING HIV PROTEASE INHIBITOR | SHIONOGI & CO., LTD. (JP) | 2017-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170253607-A1 | LONG-ACTING HIV PROTEASE INHIBITOR | CPN1, HAT1, PRSS1 | POLQ 4344/4885OPRM1 811/4885CACNA1G 3034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.